<p><strong>Diffuse Large B-cell Lymphoma Overview</strong></p>
<p>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that develops when B-lymphocytes become abnormal. It arises from the germinal center &amp;amp; post germinal center B-cells. The etiology of DLBCL is complex and multifactorial. DLBCL can arise de-novo or from the transformation of indolent diseases like chronic lymphocytic lymphoma/small lymphocytic lymphoma (so-called Richter&rsquo;s transformation), follicular lymphoma, and marginal zone lymphoma.</p>
<p>&nbsp;</p>
<h2><strong>Diffuse Large B-cell Lymphoma Epidemiology Segmentation in the 7MM</strong></h2>
<ul>
<li>Total incident cases of Diffuse Large B-cell Lymphoma</li>
<li>Gender-specific cases of Diffuse Large B-cell Lymphoma</li>
<li>Age-specific cases of Diffuse Large B-cell Lymphoma</li>
<li>Type-specific cases of Diffuse Large B-cell Lymphoma</li>
<li>Stage-specific cases of Diffuse Large B-cell Lymphoma</li>
<li>Gene type-specific cases of ABC and GCB</li>
</ul>
<h3><strong><a href="https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-epidemiology-forecast"><span style="text-decoration: underline;">Diffuse Large B-cell Lymphoma Epidemiological Insights</span></a> Observed in the 7MM (2021)</strong></h3>
<p>The total incident cases of Diffuse Large B-cell Lymphoma in the 7MM was approximately <strong>73,000 in the year 2021.</strong></p>
<h2><a href="https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market"><span style="text-decoration: underline;"><strong>Diffuse Large B-cell Lymphoma Market Insight&nbsp;</strong></span></a></h2>
<p>The market size of Diffuse Large B-cell Lymphoma in the 7MM is approximately <strong>~USD 3700 Million in the year 2021</strong>.</p>
<h3><strong>Diffuse Large B-cell Lymphoma Market Strengths</strong></h3>
<ul>
<li>The understanding of the biology of DLBCL has increased in the last years and has allowed a better understanding of the molecular mechanisms underlying the disease.</li>
</ul>
<h3><strong>Diffuse Large B-cell Lymphoma&nbsp; Market Opportunities</strong></h3>
<ul>
<li>The recent development in artificial intelligence (AI) technology has shown promising results in reducing the labor of pathologists and improving diagnostic accuracy, thus improving the market landscape.</li>
</ul>
<h3><a href="https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight"><span style="text-decoration: underline;"><strong>Diffuse Large B-cell Lymphoma Emerging drugs</strong></span></a></h3>
<p>The emerging drugs in the Diffuse Large B-cell Lymphoma market are</p>
<ul>
<li>Epcoritamab</li>
<li>Zilovertamab vedotin</li>
<li>Glofitamab</li>
<li>Plamotamab</li>
<li>Enzastaurin (DB102)</li>
<li>Mivavotinib</li>
<li>Maveropepimut-S</li>
<li>LUNSUMIO (mosunetuzumab)</li>
<li>Obe-cel</li>
<li>ALLO-501A</li>
<li>YTB323</li>
<li>Zamtocabtagene autoleucel (MB-CART2019.1)</li>
<li>Odronextamab (REGN1979)</li>
<li>Debio 1562</li>
<li>ADCETRIS (Brentuximab Vedotin)</li>
<li>Magrolimab</li>
<li>IMFINZI (durvalumab)</li>
<li>CALQUENCE (acalabrutinb)</li>
</ul>
<h3><strong>Key Diffuse Large B-cell Lymphoma Companies</strong></h3>
<p>The key players working in the&nbsp; Diffuse Large B-cell Lymphoma market are</p>
<ul>
<li>AbbVie and Genmab</li>
<li>Merck</li>
<li>Roche</li>
<li>Xencor and Janssen</li>
<li>Denovo Biopharma</li>
<li>Calithera Biosciences</li>
<li>IMV</li>
<li>Biogen</li>
<li>Autolus Therapeutics</li>
<li>Allogene Therapeutics</li>
<li>Novartis</li>
<li>Miltenyi Biomedicine</li>
<li>Regeneron Pharmaceuticals</li>
<li>Debiopharm</li>
<li>Seagen</li>
<li>Takeda</li>
<li>Gilead Sciences</li>
<li>AstraZeneca</li>
</ul>

Diffuse Large B-cell Lymphoma Market 

Diffuse Large B-cell Lymphoma  Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.